Jyong Biotech (NASDAQ:MENS) Shares Down 8% - What's Next?

Key Points

• Jyong Biotech Ltd. (NASDAQ:MENS) saw an 8% decline in share price, dropping to $46.00 during mid-day trading, significantly below its previous close of $50.00.
• Trading volume for the stock fell sharply to about 11,346 shares, down 95% from the average daily volume of 222,462 shares.
• Wall Street analysts upgraded Jyong Biotech to a "hold" rating in a research note, suggesting a cautious approach for investors.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price dropped 8% during mid-day trading on Tuesday . The company traded as low as $45.69 and last traded at $46.00. Approximately 11,346 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 222,462 shares. The stock had previously closed at $50.00.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Jyong Biotech to a "hold" rating in a research note on Monday, June 30th.

Jyong Biotech Stock Performance

The stock's 50 day moving average is $43.62.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.